指南与共识胸部肿瘤

完全切除的Ⅰ至ⅢA期非小细胞肺癌的辅助全身治疗与辅助放疗:美国临床肿瘤学会/安大略癌症治疗中心临床实践指南更新

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
指南 / 共识 · J Clin Oncol · 2017-04-24

美国临床肿瘤学会召集更新专家组,系统检索截至2016年1月的文献,并采用美国放射肿瘤学会已获ASCO认可的指南与系统评价,更新完全切除非小细胞肺癌的辅助治疗推荐。推荐ⅡA、ⅡB或ⅢA期患者常规使用以顺铂为基础的辅助化疗,ⅠB期不推荐常规使用但建议多学科评估,ⅠA期不推荐辅助化疗;Ⅰ、Ⅱ期及ⅢA期N2疾病不推荐常规辅助放疗,N2患者建议多学科评估。

要点

  • ⅡA、ⅡB或ⅢA期完全切除后推荐常规用以顺铂为基础的辅助化疗。
  • ⅠB期不推荐常规辅助化疗,但推荐术后多学科评估包括肿瘤内科会诊。
  • Ⅰ、Ⅱ期及ⅢA期N2疾病不推荐常规辅助放疗,N2患者推荐多学科评估包括放疗科会诊。

核心结论

  • 完全切除的ⅡA、ⅡB或ⅢA期非小细胞肺癌推荐常规使用以顺铂为基础的辅助化疗。
  • ⅠB期不推荐常规辅助化疗,但推荐术后多学科评估以权衡每位患者的获益与风险。
  • ⅠA期不推荐辅助化疗;Ⅰ、Ⅱ期及ⅢA期N2疾病不推荐常规辅助放疗,N2患者推荐多学科评估。

研究设计与样本

  • 美国临床肿瘤学会召集更新专家组,对完全切除非小细胞肺癌的辅助治疗进行系统文献综述。
  • 更新证据基础涵盖辅助全身治疗相关问题,包括安大略癌症治疗中心截至2016年1月的系统评价。
  • 采用已获ASCO认可的美国放射肿瘤学会指南与系统评价作为辅助放疗推荐依据。
  • 对上述系统评价进行更新并检索放疗相关研究,未发现新增随机对照试验。

主要发现

  • 更新证据基础涵盖辅助全身治疗相关问题,系统评价由安大略癌症治疗中心完成并截至2016年1月。
  • 采用美国放射肿瘤学会指南与系统评价作为辅助放疗推荐依据,更新检索未发现新增随机对照试验。
  • 指南提供除分期外需考虑的因素,包括肿瘤大小、组织病理学特征和基因改变。

关键数值与推荐

  • ⅡA、ⅡB或ⅢA期完全切除患者推荐常规使用以顺铂为基础的辅助化疗。
  • ⅠB期不推荐常规使用以顺铂为基础的辅助化疗,但推荐术后多学科评估包括肿瘤内科会诊。
  • ⅠA期不推荐辅助化疗。
  • Ⅰ或Ⅱ期完全切除患者不推荐辅助放疗。
  • ⅢA期N2疾病不推荐常规使用辅助放疗,但推荐术后多学科评估包括放疗科会诊。

临床怎么用

  • ⅡA、ⅡB或ⅢA期完全切除后按推荐常规使用以顺铂为基础的辅助化疗。
  • ⅠB期不常规使用辅助化疗,应进行术后多学科评估包括肿瘤内科会诊以评估获益与风险。
  • ⅠA期不推荐辅助化疗。
  • Ⅰ或Ⅱ期完全切除后不推荐辅助放疗。
  • ⅢA期N2疾病不常规使用辅助放疗,应进行术后多学科评估包括放疗科会诊以评估获益与风险。

局限性

  • 对系统评价的更新及放疗相关研究检索未发现新增随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant therapy guideline for resected non-small-cell lung cancers. Methods ASCO convened an update panel and conducted a systematic review of the literature, investigating adjuvant therapy in resected non-small-cell lung cancers. Results The updated evidence base covered questions related to adjuvant systemic therapy and included a systematic review conducted by Cancer Care Ontario current to January 2016. A recent American Society for Radiation Oncology guideline and systematic review, previously endorsed by ASCO, was used as the basis for recommendations for adjuvant radiation therapy. An update of these systematic reviews and a search for studies related to radiation therapy found no additional randomized controlled trials. Recommendations Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stage IIA, IIB, or IIIA disease who have undergone complete surgical resections. For individuals with stage IB, adjuvant cisplatin-based chemotherapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a medical oncologist, is recommended to assess benefits and risks of adjuvant chemotherapy for each patient. The guideline provides information on factors other than stage to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathologic features, and genetic alterations. Adjuvant chemotherapy is not recommended for patients with stage IA disease. Adjuvant radiation therapy is not recommended for patients with resected stage I or II disease. In patients with stage IIIA N2 disease, adjuvant radiation therapy is not recommended for routine use. However, a postoperative multimodality evaluation, including a consultation with a radiation oncologist, is recommended to assess benefits and risks of adjuvant radiation therapy for each patient with N2 disease. Additional information is available at www.asco.org/lung-cancer-guidelines and www.asco.org/guidelineswiki .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol. 2017. PMID: 28437162. doi:10.1200/JCO.2017.72.4401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。